Fei Tian
Analyst @ Vesalius Biocapital Partners
Fei Tian is a Series A investor at Vesalius Biocapital Partners focused on Health Care and Biotechnology. Fei Tian holds a MD (Medical Doctor) degree (2008) from Shanghai Tongji University, People’s Republic of China. She began her career as a physician in emergency medicine. During her work as a physician, she also performed research in atherosclerosis and immunology. She pursued her interest in pulmonary oncology research for her scientificific doctoral degree for a PhD at the Ludwig-Maximilian University and Thoracic Oncology Center, Munich, Germany. She has several publications as author and co-author in international peer-reviewed journals.In addition to her medical and scientific research background, she gained substantial experience of medical communication and life science consulting, including in-licensing of biological products, international market research and communication, and development of business strategies for global medtech companies and pharmaceutical companies.Fei Tian joined Vesalius Biocapital as an analyst in 2012.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Fei Tian invests in
Stages Fei Tian invests in
Countries Fei Tian invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SciRhom
|
SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development. | $68.1M / Series A / Jul 09, 2024 |
Co-Investors
Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.
Vesalius Biocapital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Fei Tian
Analyst
|
|||
Guy Geldhof
Partner
|
|||
Stephane Verdood
Managing Partner
|
|||
Alain Parthoens
Managing Partner
|
|||
Christian Schneider
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Fei Tian invest in?
Fei Tian invests primarily in Health Care and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Fei Tian?
Public channels for Fei Tian include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Fei Tian last invest?
The most recent investment recorded for Fei Tian closed in Jul 2024. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
